Trials By City
- Ashland Clinical Trials
- Bardstown Clinical Trials
- Beattyville Clinical Trials
- Bowling Green Clinical Trials
- Burkesville Clinical Trials
- Campbellsville Clinical Trials
- Carrollton Clinical Trials
- Corbin Clinical Trials
- Covington Clinical Trials
- Cynthiana Clinical Trials
- Danville Clinical Trials
- Elizabethtown Clinical Trials
- Erlanger Clinical Trials
- Florence Clinical Trials
- Fort Campbell Clinical Trials
- Fort Knox Clinical Trials
- Fort Thomas Clinical Trials
- Frankfort Clinical Trials
- Ft Mitchell Clinical Trials
- Greenville Clinical Trials
- Hartford Clinical Trials
- Hawesville Clinical Trials
- Hazard Clinical Trials
- Hebron Clinical Trials
- Henderson Clinical Trials
- Hopkinsville Clinical Trials
- Hyden Clinical Trials
- Jeffersonville Clinical Trials
- La Grange Clinical Trials
- Lawrenceburg Clinical Trials
- Lebanon Clinical Trials
- Lexington Clinical Trials
- London Clinical Trials
- Louisville Clinical Trials
- Madisonville Clinical Trials
- Monticello Clinical Trials
- Morehead Clinical Trials
- Mount Sterling Clinical Trials
- Munfordville Clinical Trials
- Murray Clinical Trials
- Nicholasville Clinical Trials
- Owensboro Clinical Trials
- Paducah Clinical Trials
- Pikeville Clinical Trials
- Pineville Clinical Trials
- Prestonsburg Clinical Trials
- Richmond Clinical Trials
- Russell Springs Clinical Trials
- Salem Clinical Trials
- Shelbyville Clinical Trials
- Somerset Clinical Trials
- Springfield Clinical Trials
- Whitesburg Clinical Trials
- Whitley City Clinical Trials
- Williamsburg Clinical Trials
Owensboro Kentucky Clinical Trials
Listings Sponsored By:
The ORBIT-AF registry will be a multicenter, prospective outpatient disease registry to identify "real world" treatment patterns of atrial fibrillation. The registry will describe this patient population with regards to demographics, clinical factors, risk stratification, and geographic regions. [more...] In particular, attention will be focused on the utilization, effectiveness, and safety of antithrombotic therapies in the prevention of stroke. The registry is designed to identify reasons and risk factors for non-receipt of anticoagulation (AC) therapy, as well as reasons why AF patients who are prescribed AC therapy do not take them.
Status: Active, not recruiting Start Date: June 2010 Completion Date: November 2014
Primary Objective: - To demonstrate that lixisenatide can reduce cardiovascular morbidity and mortality [composite endpoint of cardiovascular (CV) death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina] compared to placebo in type 2 [more...] diabetic patients who recently experienced an acute coronary syndrome (ACS) event. Secondary Objectives: To demonstrate that when compared to placebo, lixisenatide can reduce: - composite endpoint of cardiovascular death, non-fatal MI, non-fatal stroke, hospitalization for unstable angina, or hospitalization for heart failure - composite endpoint of cardiovascular death, non-fatal MI, non-fatal stroke, hospitalization for unstable angina, hospitalization for heart failure, or coronary revascularization procedure - urinary albumin excretion (based on the urinary albumin/creatinine ratio). To assess the safety and tolerability of lixisenatide.
Status: Active, not recruiting Start Date: June 2010 Completion Date: August 2014
This study is looking at whether Metformin, an agent that is commonly used to treat diabetes, can decrease or affect the ability of breast cancer cells to grow and whether Metformin will work with other therapies to keep cancer from recurring. Health Canada has [more...] not approved the sale or use of Metformin to treat breast cancer, although they have approved its use in this clinical trial. Although Metformin is approved by the FDA for the treatment of diabetes, its use in breast cancer is considered investigational.
Status: Active, not recruiting Start Date: July 2010 Completion Date: December 2016
The TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study is a prospective, observational longitudinal study to evaluate the real world effectiveness and use of prasugrel and other ADP receptor [more...] inhibitor therapies among myocardial infarction (MI) patients treated with percutaneous coronary intervention (PCI) during the index hospitalization. Patient management and treatment decisions are at the discretion of the care team per routine clinical practice. Approximately 17,000 patients will be enrolled at approximately 350 sites in the United States. Follow-up will be conducted through 15 months in approximately 15,650 patients. TRANSLATE-ACS will complement the results of both randomized controlled clinical trials and current registries in addressing the real world treatment patterns and clinical outcomes for MI patients managed with PCI and initiated on ADP receptor inhibitor therapy. In addition to determining the effectiveness of prasugrel in comparison to other ADP receptor inhibitors, the study will also determine factors associated with initial ADP receptor inhibitor selection and longitudinal patterns of use, evaluate the safety, and describe and compare resource use and medical costs associated with ADP receptor inhibitors. Additionally, this study will generate a continuum of information from the inpatient to outpatient settings to provide a comprehensive picture of patient treatment and outcomes not currently available for novel ADP receptor inhibitors.
Status: Active, not recruiting Start Date: March 2010 Completion Date: February 2014
This double-blind, parallel, two-arm study will evaluate the potential to reduce cardiovascular risk, the tolerability and long-term safety profile of aleglitazar compared to placebo on top of standard care in patients with recent acute coronary syndrome (ACS) and type [more...] 2 diabetes mellitus. Patients will be randomized to receive either aleglitazar or placebo once daily as oral doses. The study will last until at least 950 events occur, but time on study treatment will be for at least 2.5 years.
Status: Active, not recruiting Start Date: January 2010 Completion Date: November 2013
The objective of this study is to confirm the long-term safety and reliability of the Linox Lead System as used with BIOTRONIK ICDs. The GALAXY registry will provide data to fully characterize ICD lead failures, from implant through 5 years, including those failures [more...] contributing to patients losing pacing or defibrillation therapy.
Status: Active, not recruiting Start Date: December 2008 Completion Date: February 2017
The purpose of this clinical trial is to demonstrate the benefit of the immunotherapeutic product GSK1572932A when given to patients with Non-Small Cell Lung Cancer, after removal of their tumor. A course of 13 injections will be administered over 27 months. The Protocol [more...] Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Status: Active, not recruiting Start Date: October 2007 Completion Date: September 2022
This randomized phase III trial is studying doxorubicin, cyclophosphamide, and paclitaxel to see how well they work with or without bevacizumab in treating patients with lymph node-positive or high-risk, lymph node-negative breast cancer. Drugs used in chemotherapy, such as [more...] doxorubicin, cyclophosphamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of breast cancer by blocking blood flow to the tumor. Giving chemotherapy together with bevacizumab after surgery may kill any tumor cells that remain after surgery. It is not yet known whether doxorubicin, cyclophosphamide, and paclitaxel are more effective with or without bevacizumab in treating breast cancer.
Status: Active, not recruiting Start Date: November 2007 Completion Date:
This randomized phase III trial is trying to find out the best individual therapy for women who have node-negative, estrogen-receptor positive breast cancer by using a special test (Oncotype DX), and whether hormone therapy alone or hormone therapy together with [more...] combination chemotherapy is better for women who have an Oncotype DX recurrence score of 11-25. Estrogen can cause the growth of breast cancer cells. Hormone therapy may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount of estrogen the body makes. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving hormone therapy together with more than one chemotherapy drug (combination chemotherapy) has been shown to reduce the chance of breast cancer recurrence, but the benefit of adding chemotherapy to hormone therapy for women with node-negative, estrogen-receptor positive breast cancer is small. New tests may provide information about which patients are more likely to benefit from chemotherapy.
Status: Active, not recruiting Start Date: April 2006 Completion Date:
This is a Phase IIIb, multicenter, randomized, placebo-controlled trial to evaluate the safety and efficacy of chemotherapy+bevacizumab followed by bevacizumab+erlotinib versus bevacizumab+erlotinib placebo in subjects with locally advanced or metastatic NSCLC.
Status: Active, not recruiting Start Date: January 2006 Completion Date: December 2013
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known if selenium is effective in preventing the growth of new tumors in patients with previously resected non-small cell lung [more...] cancer. PURPOSE: This randomized phase III trial is studying selenium to see how well it works compared to a placebo in preventing the development of second primary lung tumors in patients who have undergone surgery to remove stage I non-small cell lung cancer.
Status: Active, not recruiting Start Date: October 2000 Completion Date:
The purpose of this study is to evaluate the safety and tolerability of memantine in pediatric (6-12 years old) patients with autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) and to identify eligible patients for participation [more...] in the follow-up randomized withdrawal study.
Status: Completed Start Date: June 2012 Completion Date: August 2013
The purpose of this Phase III study is to evaluate the long-term safety and tolerability of two fixed-dose combinations of inhaled aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo in patients with moderate to severe Chronic Obstructive Pulmonary [more...] Disease (COPD). Long-term efficacy, pharmacoeconomic and health-related quality of life assessments will also be evaluated. This extension study will include a 28 week treatment period, followed by a four week follow up visit. All patients will remain in the same treatment group as for the lead-in study and continue on one of the four treatment arms or placebo.
Status: Completed Start Date: April 2012 Completion Date: June 2013
The purpose of this study is to investigate whether LEO 90100 and calcipotriol plus betamethasone are effective in the treatment of psoriasis vulgaris.
Status: Completed Start Date: May 2012 Completion Date: November 2012
The purpose of this study is to investigate whether LEO 90100, calcipotriol and betamethasone are effective in the treatment of psoriasis vulgaris.
Status: Completed Start Date: May 2012 Completion Date: November 2012
The purpose of this trial is to determine whether a initial combination of linagliptin and metformin compared to linagliptin alone for 6 months is effective in newly diagnosed, treatment-naïve patients with Type 2 Diabetes.
Status: Completed Start Date: January 2012 Completion Date: April 2013
The aim of this study is to establish a dose-related effect of a selective 5-HT4 receptor agonist compared to placebo on residual symptoms (regurgitation with or without heartburn) in subjects with GERD who have persistent symptoms while on PPI therapy.
Status: Completed Start Date: February 2012 Completion Date: May 2013
The purpose of this Phase III study is to assess the maintenance bronchodilator effects of the fixed dose combination versus monotherapies. This study will also assess the effects of the fixed dose combination in terms of COPD symptoms, disease related health status and [more...] the long-term safety and tolerability of the fixed dose combination. This study will include a 24 week treatment period, preceding by a run-in period, followed by a two week follow up visit. All patients will be randomized to one of four treatment arms or placebo.
Status: Completed Start Date: September 2011 Completion Date: March 2013
This is a randomized, double-blind, placebo controlled, 12 week repeat oral dose, dose ranging study to determine the efficacy and safety of 3 doses of plecanatide compared to placebo in patients with Chronic Idiopathic Constipation (CIC).
Status: Completed Start Date: October 2011 Completion Date: December 2012
This study will evaluate the safety and efficacy of ranolazine compared to placebo on the average weekly angina frequency in subjects with chronic stable angina and coronary artery disease (CAD) who have a history of type 2 diabetes mellitus (T2DM). [more...] The purpose of this study is to evaluate if ranolazine can reduce the frequency of angina (chest pain) attacks, compared to a placebo. Subjects will be asked to record their daily angina episodes in a diary at the end of each study day.
Status: Completed Start Date: September 2011 Completion Date: October 2012
This is a randomized, double-blind, double-dummy, multicenter, global Phase 3 study of IV to oral TR-701 FA 200 mg once daily for 6 days versus IV to oral Zyvox® (linezolid) 600 mg every 12 hours for 10 days for the treatment of ABSSSI in [more...] adults. Patients are to start treatment with at least 2 IV doses and may receive IV therapy for the entire treatment duration. Approximately 100 to 140 sites globally will participate in this study. Patients with an ABSSSI caused by suspected or documented gram positive pathogen(s) at baseline will be randomized 1:1 to study treatment.
Status: Completed Start Date: September 2011 Completion Date: January 2013
Open-label, extension study for subjects that completed 810P202 to examine long term safety and tolerability of repeated dosing of SPN-810M as an adjunctive therapy in children with Impulsive Aggression Comorbid with Attention-Deficit/Hyperactivity Disorder (ADHD).
Status: Completed Start Date: September 2011 Completion Date: February 2013
This is an observational to evaluate Total Rhinoconjunctivitis Symptom Score and rescue medication usage (as measured by Rescue Medication Score as a Combined Score to inform the design of a phase III field study with ToleroMune Ragweed.
Status: Completed Start Date: July 2011 Completion Date: October 2011
The purpose of this study is to compare the effect of NKTR-118 with placebo in the treatment of opioid-induced constipation (OIC) in patients with cancer-related pain, including those patients that have inadequate response to laxative therapy (LIR). The study [more...] consists of 2 parts; A initial 4-week treatment period (part A) and then a 12 week extension with active treatment (part B).
Status: Completed Start Date: June 2011 Completion Date: September 2012
This is a randomized, multi-center, double blind, parallel study to compare growth and tolerance of healthy term infants fed either control or experimental infant formula.
Status: Completed Start Date: June 2011 Completion Date: December 2011
Clinical trials allow volunteers access to medical treatment options before they are available to the general public. Participants often receive the best healthcare available for their condition.
Risks are a reality, however, and may include more frequent doctor visits, health risks (possibly life-threatening), and/or the treatment being ineffective. Trials are federally regulated with strict guidelines to protect participants.
Owensboro Kentucky Clinical Trials Information presented on ClinicalTrialsSearch.org is not intended to be a substitute for qualified medical advice visit or treatment with a real physician. We are not physicians. Always consult with a medical doctor (MD). ClinicalTrialsSearch.org is a website dedicated to listing clinical research studies in human subjects, including those specifically related to Owensboro Kentucky. Clinical research trials and medical trials take place in hundreds of cities across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectiveness of new treatments and drugs. The purpose of the studies is to answer specific human health questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions. Clinical trials allow volunteers access to medical treatment options before they are available to the general public. Many times the participants receive treatment for free, and sometimes they are paid for their time. Participants often receive the best healthcare available possible for their condition. Risks are a reality, however, and may include more frequent doctor visits, health risks (possibly life-threatening), and/or the treatment being ineffective. U.S. - based Owensboro Kentucky studies are federally regulated with strict guidelines to protect patients.
There are a number of clinical trials underway to find effective treatments for diabetes, including new drugs, surgery and even transplantation.
There are several current and ongoing trials of interventions for major depressive disorder, which is characterized by a disabling combination of symptoms causing severe disruption to the sufferer's ability to carry out routine functions and tasks of daily life.
Constipation is a illness where the bowels cannot move waste material out of the body in a normal manner. There are various clinical trials recruiting participants to study the effectiveness of various treatments.